Report | SE Asia’s VC Funds: H2 2024 Review - Leaderboard

Legend Capital, Qiming back Chinese CRO startup dMed's $50m Series B

Legend Capital, Qiming back Chinese CRO startup dMed's $50m Series B

Photo by Kendal on Unsplash

Chinese clinical contract research organization (CRO) dMed Biopharmaceutical has raised 354 million yuan ($50 million) in a Series B round led by Vivo Capital, according to a media statement.